| Prev Close: | 51.50 |
|---|---|
| Open: | 51.12 |
| Bid: | 51.61 x 600 |
| Ask: | 51.62 x 500 |
| 1y Target Est: | 47.58 |
| Beta: | 0.55 |
| Next Earnings Date: | N/A |
| Day's Range: | 51.00 - 51.69 |
|---|---|
| 52wk Range: | 39.72 - 52.27 |
| Volume: | 1,179,432 |
| Avg Vol (3m): | 2,025,610 |
| Market Cap: | 64.58B |
| P/E (ttm): | 11.42 |
| EPS (ttm): | 4.52 |
| Div & Yield: | 3.80 (7.40%) |
Headlines
- 3 Neil Woodford High-Yield Sharesat Motley Fool(Tue 10:48AM EDT)
- AstraZeneca says Phase III studies of Naloxegol met primary, secondary endpointsat theflyonthewall.com(Tue 9:29AM EDT)
- InPlay: AstraZeneca presents results of two pivotal Phase III studies of naloxegol showing the 25 mg dose of the investigational drug met its primary and secondary endpoints for efficacy and showed a safety profile consistent with previousBriefing.com(Tue 9:25AM EDT)
- Results from Phase III Studies of Naloxegol for Treatment of Opioid-Induced Constipation Presented at Digestive Disease Week 2013Business Wire(Tue 9:25AM EDT)
- AstraZeneca: A Dividend Payer With An Attractive Growth Prospectat Seeking Alpha(Mon, May 20)
- Statin Users May Have a Reason to Rejoice After This Dataat Motley Fool(Sun, May 19)
- Pick Your Poison: Overweight or High Cholesterolat Motley Fool(Sun, May 19)
- 1 Giant Leap for MannKindat Motley Fool(Sat, May 18)
- 3 Healthcare Stocks Stories To Close Out the Trading Weekat Wall St. Cheat Sheet(Fri, May 17)
- Impax Labs launches generic version of ZomigAP(Fri, May 17)
- Impax commenced shipment of authorized generic Zomigtheflyonthewall.com(Fri, May 17)
- Good News for Roche's TarcevaZacks(Thu, May 16)
- Cheerleaders: Look Beyond Pharma For JobsYCharts(Thu, May 16)
- Is AstraZeneca Gearing Up for a Shopping Spree?at Motley Fool(Wed, May 15)
- Array Biopharma: Measuring The Strength Of This Small-Cap Pharma Stockat Seeking Alpha(Wed, May 15)
Press Releases
- Results from Phase III Studies of Naloxegol for Treatment of Opioid-Induced Constipation Presented at Digestive Disease Week 2013Business Wire(Tue 9:25AM EDT)
- Assessing Your Asthma is Key to Taking ControlPR Newswire(Mon, May 13)
- Sub-Group Analysis Shows Investigational Metreleptin Treatment Demonstrated Reductions in HbA1c, Triglycerides and Liver Function Tests in Pediatric Patients with Lipodystrophy During a 12-Month PeriodBusiness Wire(Mon, May 6)
Reports
- ValuEngine Industry Report for Large CAP PharmaValuEngine, Inc.(May 21)
- Market Edge Equity Research ReportMarket Edge(May 20)
- AstraZeneca ADSS&P Capital IQ – STARS Reports(May 18)
